Compounds > laxaphycin a
Page last updated: 2024-11-12

laxaphycin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Laxaphycin A: cyclic peptide from blue-green algae [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16116570
CHEMBL ID434574
MeSH IDM0488767

Synonyms (7)

Synonym
laxaphycin a
CHEMBL434574
MLS003235795
smr001918759
cyclo[d-alloisoleucyl-l-leucylglycyl-(3r)-3-aminooctanoyl-l-homoseryl-(2e)-2-amino-2-butenoyl-(4r)-4-hydroxy-l-prolyl-l-homoseryl-d-phenylalanyl-d-leucyl-l-isoleucyl]
DTXSID001339230
145680-51-9
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1594463Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability measured after 24 hrs by LDH release assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure and biological evaluation of new cyclic and acyclic laxaphycin-A type peptides.
AID1391568Synergistic antiproliferative activity against human HCT116 cells assessed as combination index at 100 uM after 48 hrs in presence of 10 uM laxaphycin B4 by MTT assay2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Discovery of new A- and B-type laxaphycins with synergistic anticancer activity.
AID1391560Synergistic antiproliferative activity against human HCT116 cells assessed as combination index at 10 uM after 48 hrs in presence of 0.32 uM laxaphycin B4 by MTT assay2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Discovery of new A- and B-type laxaphycins with synergistic anticancer activity.
AID1594462Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability measured after 6 hrs by MTT assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure and biological evaluation of new cyclic and acyclic laxaphycin-A type peptides.
AID1391567Synergistic antiproliferative activity against human HCT116 cells assessed as combination index at 320 uM after 48 hrs in presence of 32 uM laxaphycin B4 by MTT assay2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Discovery of new A- and B-type laxaphycins with synergistic anticancer activity.
AID280538Antiproliferative activity against human DLD1 cells at 5 uM after 48 hrs by RRT assay2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Total structure and inhibition of tumor cell proliferation of laxaphycins.
AID1391562Synergistic antiproliferative activity against human HCT116 cells assessed as combination index at 1 uM after 48 hrs in presence of 0.032 uM laxaphycin B4 by MTT assay2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Discovery of new A- and B-type laxaphycins with synergistic anticancer activity.
AID1391558Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Discovery of new A- and B-type laxaphycins with synergistic anticancer activity.
AID280519Cytotoxicity against drug-sensitive CCRF-CEM cells after 72 hrs2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Total structure and inhibition of tumor cell proliferation of laxaphycins.
AID280520Cytotoxicity against vinblastine-resistant CEM/VLB100 cells after 72 hrs2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Total structure and inhibition of tumor cell proliferation of laxaphycins.
AID1391557Synergistic antiproliferative activity against human HCT116 cells assessed as combination index at 10 uM after 48 hrs in presence of 1 uM laxaphycin B4 by MTT assay2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Discovery of new A- and B-type laxaphycins with synergistic anticancer activity.
AID1391571Synergistic antiproliferative activity against human HCT116 cells assessed as combination index at 1 uM after 48 hrs in presence of 0.1 uM laxaphycin B4 by MTT assay2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Discovery of new A- and B-type laxaphycins with synergistic anticancer activity.
AID280521Cytotoxicity against teniposide-resistant CEM/VM1 cells after 72 hrs2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Total structure and inhibition of tumor cell proliferation of laxaphycins.
AID1391569Synergistic antiproliferative activity against human HCT116 cells assessed as combination index at 32 uM after 48 hrs in presence of 3.2 uM laxaphycin B4 by MTT assay2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Discovery of new A- and B-type laxaphycins with synergistic anticancer activity.
AID1594461Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability measured after 24 hrs by MTT assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure and biological evaluation of new cyclic and acyclic laxaphycin-A type peptides.
AID1391570Synergistic antiproliferative activity against human HCT116 cells assessed as combination index at 3.2 uM after 48 hrs in presence of 0.32 uM laxaphycin B4 by MTT assay2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Discovery of new A- and B-type laxaphycins with synergistic anticancer activity.
AID1391559Synergistic antiproliferative activity against human HCT116 cells assessed as combination index at 32 uM after 48 hrs in presence of 1 uM laxaphycin B4 by MTT assay2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Discovery of new A- and B-type laxaphycins with synergistic anticancer activity.
AID280524Antiproliferative activity against CCRF-CEM cells at 20 uM after 72 hrs2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Total structure and inhibition of tumor cell proliferation of laxaphycins.
AID1391561Synergistic antiproliferative activity against human HCT116 cells assessed as combination index at 3.2 uM after 48 hrs in presence of 0.1 uM laxaphycin B4 by MTT assay2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Discovery of new A- and B-type laxaphycins with synergistic anticancer activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's2 (50.00)24.3611
2020's1 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.13 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
vinblastine
[no description available]		2.0310
laxaphycin b
Laxaphycin B: cyclic peptide from blue-green algae		2.4920
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		02.2510
Malignant Melanoma
[description not available]		02.2510
Cancer of Ovary
[description not available]		02.2510
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.2510
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.2510
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.2510